Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 214 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Immunodeficiency Virus I Infection Clear all
Recruiting Phase 1Phase 2 Interventional

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255
View directory record Official record
Conditions
HIV Infection
Interventions
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, Dolutegravir (DTG), VRC07-523LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 48 Hours
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 28, 2026, 10:35 AM EDT
Completed No phase listed Observational

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

NCT00029913
View directory record Official record
Conditions
HIV Infections
Interventions
Observation
Other
Lead sponsor
HIV Vaccine Trials Network
Network
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2010 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

NCT00004579
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

NCT00046176
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
abacavir/lamivudine, abacavir, lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
52
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

NCT01227824
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

NCT01967771
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, CBZ
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00000865
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 13 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

NCT01138072
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2248761, Simvastatin, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 28, 2026, 10:35 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Botswana Study of UC-781 Vaginal Microbicide

NCT00385554
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781 carbomer gel, 0.1% and 0.25%
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
21 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Atlanta, Georgia • Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children

NCT00000761
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon gamma-1b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Protease Inhibitors

NCT00774735
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Hepatic Impairment Study

NCT01231529
View directory record Official record
Conditions
Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1349572
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test

NCT06368453
View directory record Official record
Conditions
Human Immunodeficiency Virus I Infection, Human Immunodeficiency Virus II Infection
Interventions
INSTI® HIV Self-Test
Device
Lead sponsor
bioLytical Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

NCT00002353
View directory record Official record
Conditions
HIV Infections
Interventions
P3C541b Lipopeptide
Biological
Lead sponsor
United Biomedical
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

NCT00002009
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Sargramostim
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Methotrexate for HIV Infection

NCT00000834
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Methotrexate, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Wichita, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 2 Interventional

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

NCT00257621
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW640385, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 10:35 AM EDT
Not listed No phase listed Observational

Evaluation of the MP Diagnostics HTLV Blot 2.4

NCT01467024
View directory record Official record
Conditions
HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
Interventions
CDPHL Algorithm
Other
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Richmond, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

NCT00708162
View directory record Official record
Conditions
HIV Infection
Interventions
Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
94
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Sep 28, 2026, 10:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

NCT02797470
View directory record Official record
Conditions
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Melphalan, Peripheral Blood Stem Cell Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
4
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

NCT02388594
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
ZFN Modified CD4+ T Cells, Cyclophosphamide
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Tenofovir Disoproxil Fumarate to Treat Pediatric HIV

NCT00024986
View directory record Official record
Conditions
HIV Infection
Interventions
Tenofovir DF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

NCT00044577
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
abacavir/lamivudine, abacavir, lamivudine, tenofovir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 28, 2026, 10:35 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

NCT07392372
View directory record Official record
Conditions
HIV -1 Infection
Interventions
BNT351, Placebo
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 28, 2026, 10:35 AM EDT